SENORES PHARMACEUTICALS L

Senores Pharmaceuticals Limited held its Q1 FY27 earnings conference call on July 27, 2026, where management reported a strong performance driven by strategic priorities and operational excellence. The company achieved a consolidated revenue of INR 180 crores, reflecting a 36% year-over-year growth, with regulated markets growing by 42% and emerging markets by 30%. Management highlighted a robust product pipeline, with 58 approved ANDAs and plans for 35 more commercializations in the next 18 to 20 months. The EBITDA for the quarter was INR 54 crores, up 87% year-over-year, and profit after tax grew by 56% to INR 31 crores. Management set a revenue growth goal of 30% to 40% and PAT growth of 50% to 60% for FY27, supported by a strong product pipeline and operational improvements. The call concluded with management expressing confidence in sustaining growth momentum and delivering strong performance in the future.

Management emphasized strong growth and operational performance.